A phase I study of combined docetaxel and repeated high activity Re-186-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)

J.M. Van Dodewaard-de Jong, J.M.H. De Klerk, H.J. Bloemendal, B.P.J. Van Bezooijen, M.J. De Haas, Richard Wilson, Joe O'Sullivan

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Purpose Bone-seeking radiopharmaceuticals have palliative benefit in castration-resistant prostate cancer (CRPC) metastatic to bone. Recent studies have shown improvement of survival and quality of life when radiopharmaceuticals were given repeatedly or in combination with chemotherapy. We designed a phase I study combining docetaxel and Re-186-labelled hydroxyethylidene diphosphonate (HEDP) in men with CRPC and bone metastases to evaluate toxicity.
Original languageEnglish
Pages (from-to)1990-1998
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume38
Issue number11
DOIs
Publication statusPublished - Nov 2011

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'A phase I study of combined docetaxel and repeated high activity Re-186-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)'. Together they form a unique fingerprint.

Cite this